Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted fourteen new employees options to purchase a total of 61,000 shares of the company's common stock at an exercise price per share of $33.03 which was the closing price on march 8, 2022, and restricted stock units to acquire a total of 30,500
RCUS Ratings Summary
RCUS Quant Ranking